Data from Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework

• DOI: 10.1158/1078-0432.c.6529016.v1
• Publication Date: 2023-04-01T06:21:06Z
• Authors: Ida Netterberg; Mats O. Karlsson; Leon W.M.M. Terst...; Miriam Koopman; Cornelis J.A. Punt; Lena E. Friberg
• Keywords: Circulating tumor cell; Pharmacodynamics

<div>AbstractPurpose:<p>Quantitative relationships between treatment-induced changes in tumor size and circulating cell (CTC) counts, their links to overall survival (OS), are lacking. We present a population modeling framework identifying quantifying such relationships, based on longitudinal data collected patients with metastatic colorectal cancer (mCRC) evaluate the value of CTC counts as predictors OS.</p>Experimental Design:<p>A pharmacometric approach (i.e., pharmacodynamic modeling) was used characterize count them OS 451 mCRC treated chemotherapy targeted therapy prospectively randomized phase III study (CAIRO2).</p>Results:<p>A model quiescence drug resistance time-course, was, addition total normalized dose all administered drugs) given cycle, related through negative binomial (CTC model). Tumor did not contribute additional predictive when mean predictor OS. Treatment reduced typical from 1.43 0.477 (HR = 3.94). The applied explore whether modifications (increased reduced) would result below 1/7.5 mL after 1 2 weeks treatment.</p>Conclusions:<p>Time-varying can be useful for early predicting mCRC, may therefore have potential model-based treatment individualization. Although connected CTC, its link weaker.</p></div>